Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437142 | 1.00 | MAPT (0.41) | MAPTTSHRHPGDSMN1; SMN2POLB | |
| SCHEMBL13964305 | 0.95 | ALOX12 (0.40) | MAPTTSHRHPGDSMN1; SMN2POLB | |
| SCHEMBL13939428 | 0.93 | HDAC1 (0.40) | MAPTTSHRHPGDSMN1; SMN2POLB | |
| SCHEMBL13964354 | 0.92 | ALOX12 (0.44) | MAPTTSHRSMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL13964341 | 0.87 | ALOX5 (0.45) | TSHRHPGDPOLBL3MBTL1KMT2A | |
| SCHEMBL13939445 | 0.85 | ALOX12 (0.39) | MAPTTSHRHPGDSMN1; SMN2POLB | |
| SCHEMBL13939361 | 0.85 | CYP1A2 (0.41) | MAPTTSHRPOLBL3MBTL1KMT2A | |
| SCHEMBL13939391 | 0.85 | F2RL1 (0.45) | MAPTTSHRSMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL13939392 | 0.84 | ALOX12 (0.41) | MAPTTSHRSMN1; SMN2POLBKMT2A | |
| SCHEMBL13939409 | 0.84 | L3MBTL1 (0.35) | MAPTTSHRHPGDSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | F3, TBCA, GYPA | MAPT 2875/4885TSHR 3881/4885HPGD 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.